Bickel M, Herling A W, Schoelkens B, Scholtholt J
Dept. of Pharmacology, Hoechst AG, Frankfurt, FRG.
Scand J Gastroenterol Suppl. 1988;146:78-88. doi: 10.3109/00365528809099134.
Roxatidine acetate is a specific and competitive H2-receptor antagonist, as shown in isolated rabbit gastric glands or guinea pig atria preparations. The antisecretory effect of roxatidine acetate is mediated by its main metabolite, roxatidine. In the rat, roxatidine acetate was equipotent after intraduodenal and intraperitoneal administration, indicating excellent bioavailability. Roxatidine acetate and roxatidine were equipotent in the rat after intravenous administration. In the Heidenhain-pouch dog stimulated by food ingestion or maximal histamine dosing, roxatidine acetate and roxatidine proved to be 3-6 times more potent than cimetidine in inhibiting gastric acid secretion. From in vitro experiments it can be concluded that roxatidine acetate and ranitidine are equipotent. Roxatidine acetate has no antiandrogenic effects and does not influence drug-metabolizing enzymes in the liver.
醋酸罗沙替丁是一种特异性竞争性H2受体拮抗剂,这在离体兔胃腺或豚鼠心房制备实验中得到证实。醋酸罗沙替丁的抗分泌作用由其主要代谢产物罗沙替丁介导。在大鼠中,十二指肠内给药和腹腔内给药后,醋酸罗沙替丁的效力相当,表明其生物利用度极佳。静脉给药后,醋酸罗沙替丁和罗沙替丁在大鼠中的效力相当。在因摄入食物或给予最大组胺剂量而受到刺激的海登海因小胃犬中,醋酸罗沙替丁和罗沙替丁在抑制胃酸分泌方面的效力比西咪替丁强3至6倍。从体外实验可以得出结论,醋酸罗沙替丁和雷尼替丁的效力相当。醋酸罗沙替丁没有抗雄激素作用,也不影响肝脏中的药物代谢酶。